by The peptide therapeutics market comprises therapies that are based on single peptide or multiple peptides for the treatment of various diseases. Peptide therapeutics provides several advantages over small molecule drugs such as high selectivity, low toxicity, and ease of availability. Increasing demand for customized peptide-based drugs along with limited side effects associated with peptides have boosted the adoption of peptide therapeutics globally.
The Global Peptide Therapeutics Market is estimated to be valued at US$ 51133.71 Bn in 2024 and is expected to exhibit a CAGR of 8.9% over the forecast period 2024 to 2030.
Key players operating in the Peptide Therapeutics are IBM Corporation, SAP SE, Oracle Corporation, ABB Ltd., Infor, Inc., Ultimo Software Solutions BV, CARL International SA, eMaint Enterprises, LLC, Mainsaver, Inc., MEX Pty Ltd., Asset Works LLC, and CGI, Inc. Peptide therapeutics have emerged as viable alternatives owing to their high potency, greater stability and relative safety over small molecule drugs. This has boosted the demand for peptide therapeutics globally. With advancements in technology, key players are expanding their manufacturing capabilities and infrastructure to cater to the rising demand.
The growing demand for customized therapies has boosted research and development for developing peptide-based drugs. Peptide therapeutics provide several advantages over small molecules such as high specificity, better tolerability and fewer side effects. This is positively impacting the adoption of peptide drugs globally. Their ease of synthesis is also fueling innovation in the market.
Major players are expanding their presence globally to leverage Global Peptide Therapeutics Market Size opportunities. North America dominates the market owing to the presence of well-established medical infrastructure and high healthcare spending. However, Asia Pacific is expected to witness high growth owing to growing healthcare expenditure and increasing research activities in the area of peptide therapeutics.
Market Key Trends
Personalized medicine is emerging as a key trend in the peptide therapeutics market. Growing focus on customized therapies to improve treatment outcomes is boosting innovation. Manufacturers are developing peptides catering to genetics, lifestyle and environment of the individual. This promises to enhance efficacy and safety. Furthermore, the use of artificial intelligence and machine learning for identification of disease-specific peptide biomarkers is also gaining traction. This is expected to aid in developing disease modifying peptide drugs with higher selectivity and potency. Sustained focus on R&D along with advancement in technologies will further drive the peptide therapeutics domain in the coming years.
Porter’s Analysis
Threat of new entrants: The Peptide Therapeutics market requires large investments in R&D which act as entry barriers for new players. However, small biotech companies can occupy niche segments of the market with specialized products.
Bargaining power of buyers: Individual consumers have low bargaining power in the Peptide Therapeutics market due to lack of information and difficulties in differentiating amongst products. However, large pharmaceutical companies and healthcare institutions have significant bargaining power due to their purchasing abilities.
Bargaining power of suppliers: A few key players dominate the supply of raw materials required for peptide production including specialized equipment. However, availability of generic alternatives provides some counterbalance to suppliers’ bargaining power.
Threat of new substitutes: Due to intense R&D investment in biosimilars, biologics and other drug delivery mechanisms, threat of substitution exists for peptide therapeutics. Substitution depends on therapeutic area and availability of better treatment alternatives.
Competitive rivalry:
The market is moderately competitive and characterized by intense non-price competition in innovation and product differentiation. Rivalry is expected to increase further with the entry of biosimilars and advancement of drug delivery mechanisms.
Geographical Regions: North America accounted for the major share in the global peptide therapeutics market in 2022, owing to high healthcare expenditure and growing R&D activities in the region. Additionally, Asia Pacific is projected to witness the fastest growth over the forecast period, attributable to increasing healthcare investment, rising geriatric population and growing prevalence of chronic diseases.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
